ly3437943 retatrutide triple agonist glp-1 gip glucagon LY3437943, a novel glucagon, GIP, and receptor for glycemic control and weight loss: From discovery to clinical proof of concept Alluvi Retatrutide 40 mg |

70 For example, compound 2j, a triazole-containing derivative, has demonstrated high potency and comparable efficacy to danuglipron in preclinical studies, suggesting it could serve as a lead compound for further development

DR is a serious complication of diabetes that can ultimately lead to blindness

Fusco J et al (2017): GLP-1/Exendin-4 induces -cell proliferation via the epidermal growth factor receptor

Theyre serious medications with strict usage requirements that are intended for chronic weight management

Long-term safety and efficacy of glucagon-like peptide-1 receptor agonists in individuals with obesity and without type 2 diabetes: A global retrospective cohort study